Atara Biotherapeutics, Inc.ATRANASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank87
3Y CAGR+49.3%
5Y CAGR-14.6%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+49.3%/yr
vs +37.4%/yr prior
5Y CAGR
-14.6%/yr
Recent acceleration
Acceleration
+11.8pp
Accelerating
Percentile
P87
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 41.79% |
| Q3 2025 | -33.74% |
| Q2 2025 | 73.99% |
| Q1 2025 | -14.99% |
| Q4 2024 | -513.46% |
| Q3 2024 | 62.53% |
| Q2 2024 | 64.05% |
| Q1 2024 | 41.25% |
| Q4 2023 | 1.83% |
| Q3 2023 | 2.75% |
| Q2 2023 | -37.39% |
| Q1 2023 | 32.44% |
| Q4 2022 | 12.57% |
| Q3 2022 | -1.71% |
| Q2 2022 | 24.33% |
| Q1 2022 | -146.66% |
| Q4 2021 | 41.90% |
| Q3 2021 | 4.22% |
| Q2 2021 | 6.27% |
| Q1 2021 | -1494.61% |
| Q4 2020 | 92.22% |
| Q3 2020 | 6.49% |
| Q2 2020 | 15.52% |
| Q1 2020 | -14.23% |
| Q4 2019 | -12.55% |
| Q3 2019 | 4.47% |
| Q2 2019 | 22.24% |
| Q1 2019 | -22.26% |
| Q4 2018 | -19.38% |
| Q3 2018 | -21.97% |
| Q2 2018 | -13.24% |
| Q1 2018 | -39.63% |
| Q4 2017 | -23.28% |
| Q3 2017 | 0.35% |
| Q2 2017 | 7.87% |
| Q1 2017 | -4.11% |
| Q4 2016 | -35.82% |
| Q3 2016 | -44.44% |
| Q2 2016 | 13.63% |
| Q1 2016 | -9.65% |